ABSTRACT
During the same period, systemic therapies have become tailored to an individual patient’s tumor biology. Advances include endocrine therapy with aromatase inhibitors, novel chemotherapeutic agents, and targeted therapies. Radiation therapies which traditionally focused on whole-breast irradiation are now being examined in partial and accelerated forms. In conjunction with advances in local therapy to the breast and systemic therapies, the status of axillary lymph nodes and method of evaluation remains an important part of staging a patient’s breast cancer in addition to improving local control and providing information for adjuvant treatment recommendations (7).
